VIRGINIA RETIREMENT SYSTEMS ET Al Invests $1.16 Million in AnaptysBio, Inc. $ANAB

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in AnaptysBio, Inc. (NASDAQ:ANAB) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 17,250 shares of the biotechnology company’s stock, valued at approximately $1,164,000.

Several other institutional investors also recently bought and sold shares of the stock. California State Teachers Retirement System grew its position in AnaptysBio by 8,399.7% during the 2nd quarter. California State Teachers Retirement System now owns 1,189,958 shares of the biotechnology company’s stock worth $80,322,000 after acquiring an additional 1,175,958 shares during the last quarter. Irenic Capital Management LP bought a new stake in AnaptysBio in the second quarter valued at approximately $4,755,000. Ancora Advisors LLC bought a new stake in AnaptysBio in the second quarter valued at approximately $338,000. Hsbc Holdings PLC boosted its stake in shares of AnaptysBio by 72.6% during the second quarter. Hsbc Holdings PLC now owns 216,949 shares of the biotechnology company’s stock valued at $14,928,000 after purchasing an additional 91,232 shares during the period. Finally, Palo Alto Investors LP purchased a new stake in shares of AnaptysBio during the second quarter valued at approximately $40,735,508.

AnaptysBio Stock Performance

Shares of ANAB stock opened at $53.87 on Friday. AnaptysBio, Inc. has a fifty-two week low of $11.40 and a fifty-two week high of $72.36. The firm has a market cap of $1.60 billion, a P/E ratio of -49.88 and a beta of 0.71. The business’s 50 day moving average price is $57.23 and its 200-day moving average price is $59.24.

Wall Street Analyst Weigh In

Several brokerages recently commented on ANAB. TD Cowen decreased their target price on shares of AnaptysBio from $75.00 to $70.00 and set a “buy” rating on the stock in a research note on Tuesday, August 25th. Wolfe Research reissued an “outperform” rating and set a $78.00 price target on shares of AnaptysBio in a research report on Monday, August 31st. HC Wainwright reissued a “buy” rating and issued a $95.00 price target on shares of AnaptysBio in a report on Monday, August 24th. Scotiabank lowered shares of AnaptysBio to a “hold” rating and set a $70.00 price target on the stock. in a report on Tuesday, August 25th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of AnaptysBio in a research report on Friday, August 7th. Eleven research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $79.85.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for cancer and immune-mediated diseases. The company’s programs are designed to modulate immune-cell signaling and address conditions in which the immune system is either insufficiently active, as in cancer, or overly active, as in autoimmune and inflammatory disorders.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody targeting CD200R1, and other immune-cell modulators aimed at autoimmune and inflammatory diseases.